The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+), well differentiated Grade1 and Grade 2 (G1 and G2) (Ki-67 \<10%) advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with high disease burden
Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
This trial is no longer recruiting — here are similar active trials
Matched by cancer type/biomarker, currently recruiting.
The goal of this clinical trial is to learn if the OATD-02 administration (orally) in monotherapy is safe and has the pharmacodynamic potential to restore and enhance tumour responses to immunotherapy through increased arginine levels or intrinsic anti-tumour activity in participants with advanced metastatic colorectal cancer, ovarian cancer, renal cancer or pancreatic cancer.
The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2.
Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase.
About the trial
The Florida Pancreas Collaborative wants to partner with individuals who are known to have, or are suspected to have a pancreatic lesion, tumor, cyst, mass, cancer, or pancreatitis and are undergoing diagnosis and treatment at a participating institution. The goals of this project are to build a large database of information obtained from blood, tissue, medical images, surveys and information from routine care to develop noninvasive diagnostic approaches that could be used as decision-making tools to effectively personalize clinical care.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Podejrzenie lub rozpoznanie zmiany, cysty, guza lub raka trzustki na podstawie objawów, badań obrazowych lub wyników krwi
- •Pacjent nie otrzymywał dotychczas żadnego leczenia trzustki
- •Zdolność do zrozumienia informacji o badaniu i dobrowolne podpisanie zgody
- •Chęć wypełnienia ankiet i przekazania zdjęć medycznych oraz próbek krwi, płynu lub tkanki
✗ Disqualifies
- •Brak podejrzenia lub rozpoznania zmiany trzustki
- •Pacjent już przeszedł leczenie trzustki (operacja, chemioterapia, radioterapia)
- •Niemożliwość udzielenia świadomej zgody na uczestnictwo
- •Niechęć do wypełniania ankiet lub przekazywania próbek
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 23, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Florida Research Institute (FRI)
Lakewood Rch, United States
Sylvester Comprehensive Cancer Center & Jackson Memorial Hospital
Miami, United States
Moffitt Cancer Center
Tampa, United States
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/18/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.